Document is current
Any future updates will be listed below
-
Authors
Tosh, Christopher
Tec, Mauricio
White, Jessica B. https://orcid.org/0000-0001-5748-8383
Quinn, Jeffrey F. https://orcid.org/0000-0002-5414-9957
Ibanez Sanchez, Glorymar
Calder, Paul
Kung, Andrew L. https://orcid.org/0000-0002-9091-488X
Dela Cruz, Filemon S. https://orcid.org/0000-0002-8356-5191
Tansey, Wesley https://orcid.org/0000-0002-5294-4228
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37 CA271186, U54CA274492, P30 CA008748)
- License Information
-
More Information
Article History
Received: 9 April 2024
Accepted: 5 December 2024
First Online: 2 January 2025
Competing interests
: The Authors declare the following competing interests. J.B.W. has contract employment and equity interest in SpringWorks Therapeutics. F.D.C. receives institutional research support from Eisai Co. and Y-mAbs Therapeutics. A.L.K. is on the Scientific Advisory Board of Emendo Biotherapeutics, Karyopharm Therapeutics, Imago BioSciences, and DarwinHealth; is co-Founder and on the Scientific Advisory Board of Isabl; has equity interest in Imago BioSciences, Emendo Biotherapeutics and Isabl; and receives royalty income from Labcorp. The remaining authors declare no competing interests.
